6:34 PM
 | 
Oct 31, 2012
 |  BC Extra  |  Clinical News

Researchers report solanezumab biomarker data

Researchers at the University of California, San Francisco said an independent analysis of pooled data from the Phase III EXPEDITION1 and EXPEDITION2 trials to treat mild to moderate Alzheimer's disease (AD) showed that IV solanezumab from Eli Lilly and Co. (NYSE:LLY) non-significantly reduced blood levels of beta amyloid in...

Read the full 239 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >